Quick answer: MOTS-c and Humanin are both mitochondrial-derived peptides (encoded in mitochondrial DNA), but they’re studied for different roles. MOTS-c is researched as a metabolic regulator — an “exercise mimetic” that activates AMPK and improves insulin sensitivity. Humanin is researched mainly as a cytoprotective, anti-apoptotic peptide acting through GP130/STAT3 signaling, with neuroprotective and cardiovascular interest. Sold for research use only.
The core distinction
The simplest framing: MOTS-c is the “metabolism” mitochondrial peptide; Humanin is the “cell-survival” mitochondrial peptide. Both originate inside the mitochondrion, but MOTS-c research centers on energy and glucose handling, while Humanin research centers on protecting cells from stress and apoptosis.
Side-by-side
| MOTS-c | Humanin | |
|---|---|---|
| Origin | Mitochondrial-derived peptide (16 amino acids, from 12S rRNA region) | Mitochondrial-derived peptide (21–24 amino acids, from 16S rRNA region) |
| Primary studied mechanism | AMPK activation; folate-cycle/AICAR pathway; insulin sensitivity | GP130/STAT3 signaling; anti-apoptotic, cytoprotective |
| Main research angle | Metabolic regulation, glucose handling, “exercise mimetic” | Neuroprotection, apoptosis inhibition, cardiovascular protection |
| Behaves like | A circulating metabolic hormone (rises with exercise, declines with age) | A stress-response/cytoprotective factor |
Mechanisms in more detail
MOTS-c acts largely through AMPK. Research (Lee et al., Cell Metabolism, 2015) showed it inhibits the folate cycle and de novo purine biosynthesis, causing AICAR to accumulate; elevated AICAR activates AMPK, which then promotes insulin sensitivity and glucose uptake — effects that mirror the metabolic adaptations of aerobic exercise. MOTS-c is detectable in plasma, rises with exercise and caloric restriction, and declines with age, so it’s framed as a metabolic hormone.
Humanin works through a different axis. It signals via the GP130 receptor complex and STAT3, and is studied chiefly for cytoprotection — inhibiting apoptosis and protecting neurons and cardiomyocytes from stress. It also enhances insulin sensitivity through STAT3 signaling, but its defining research role is cell survival rather than metabolic drive.
Why researchers study them together
Because they’re complementary mitochondrial signals — MOTS-c driving AMPK-based metabolic adaptation and Humanin providing cytoprotection — the two are studied together in mitochondrial-health and longevity research, often alongside NAD+ and Epitalon. PTW offers both individually.
Frequently asked questions
What is the difference between MOTS-c and Humanin?
MOTS-c is studied as a metabolic regulator that activates AMPK and improves insulin sensitivity; Humanin is studied as a cytoprotective, anti-apoptotic peptide acting through GP130/STAT3. Both are mitochondrial-derived.
What does it mean that they are “mitochondrial-derived peptides”?
Both are encoded within mitochondrial DNA (MOTS-c from the 12S rRNA region, Humanin from the 16S rRNA region) rather than in the cell nucleus — a distinct class of signaling peptides.
Which one is the “exercise mimetic”?
MOTS-c. Its AMPK-driven effects on glucose handling and insulin sensitivity closely mirror the adaptations produced by aerobic exercise.
What is Humanin mainly studied for?
Cytoprotection — inhibiting apoptosis and protecting neurons and heart cells from stress — plus neuroprotective and cardiovascular research roles.
Are these for human use?
No. Portal to Wellness sells these strictly for laboratory and research use only. Nothing here is medical advice.
Primary-literature anchors
Cite primary sources: Lee et al. (MOTS-c, AMPK and insulin sensitivity, Cell Metabolism, 2015); Hashimoto et al. and Cohen/Lee groups (Humanin discovery and GP130/STAT3 cytoprotection, PNAS and related). Link via PubMed.
Related research & products
For research use only. Not for human or veterinary use, diagnosis, treatment, or prevention of any condition. Not evaluated by the FDA. Author: Charles Fowler. Last updated: May 2026.